Acute and chronic effects of desvenlafaxine on gastrointestinal transit and motility in dogs

Neurogastroenterology and Motility

Volumn 25, Issue 10, 2013, Pages

  Song, J ^a   Yin, J ^a   Chen, J D Z ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Ningbo Pace Translational Medical Research Center   (China)

Author keywords

Antidepressant; Colon motility; Gastric emptying; Intestinal transit

Indexed keywords

DESVENLAFAXINE; GUANETHIDINE;

AGITATION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOG; DRUG EFFECT; FEMALE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HYPERSALIVATION; NONHUMAN; PRIORITY JOURNAL; STOMACH EMPTYING; SYMPATHETIC FUNCTION; VOMITING;

ANTIDEPRESSANT; COLON MOTILITY; GASTRIC EMPTYING; INTESTINAL TRANSIT;

ANIMALS; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DOGS; FEMALE; GASTROINTESTINAL TRANSIT; MUSCLE CONTRACTION; MUSCLE, SMOOTH;

EID: 84884708031     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12190     Document Type: Article

References (37)

1. Perry R, Cassagnol M. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther 2009; 31(Pt 1): 1374-404.
2. Lieberman DZ, Massey SH. Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Core Evid 2010; 4: 67-82.
3. Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr 2009; 14: 41-50.
4. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008; 24: 1877-90.
5. Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007; 68: 1663-72.
6. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007; 68: 677-88.
7. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007; 22: 338-47.
8. Lieberman DZ, Montgomery SA, Tourian KA et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 2008; 23: 188-97.
9. Lieberman DZ, Massey SH. Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Core Evid 2010; 4: 67-82.
10. Deecher DC, Beyer CE, Johnston G et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006; 318: 657-65.
11. Hashash JG, Abdul-Baki H, Azar C et al. Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia. Aliment Pharmacol Ther 2008; 27: 1148-55.
12. van Kerkhoven LA, Laheij RJ, Aparicio N et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008; 6: 746-52; quiz 718.
13. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
14. Dai F, Lei Y, Chen JD. Inhibitory effects of desvenlafaxine on gastric slow waves, antral contractions and gastric accommodation mediated via the sympathetic mechanism in dogs. Am J Physiol Gastrointest Liver Physiol 2011; 301: G707-12.
15. Yin J, Chen J. Excitatory effects of synchronized intestinal electrical stimulation on small intestinal motility in dogs. Am J Physiol Gastrointest Liver Physiol 2007; 293: G1190-5.
16. Chen J, Koothan T, Chen JD. Synchronized gastric electrical stimulation improves vagotomy-induced impairment in gastric accommodation via the nitrergic pathway in dogs. Am J Physiol Gastrointest Liver Physiol 2009; 296: G310-8.
17. Chen J, Lin L, Chen JDZ. Colorectal and rectocolic reflexes in canines: involvement of tone, compliance and anal sphincter relaxation. Neurogastroenterol Motil 2009; 21(S1): 20.
18. Preskorn S, Patroneva A, Silman H et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009; 29: 39-43.
19. Chen J, Song GQ, Yin J, Koothan T, Chen JD. Electroacupuncture improves impaired gastric motility and slow waves induced by rectal distension in dogs. Am J Physiol Gastrointest Liver Physiol 2008; 295: G614-20.
20. Chen JH, Sallam HS, Lin L, Chen JD. Colorectal and rectocolonic reflexes in canines: involvement of tone, compliance, and anal sphincter relaxation. Am J Physiol Regul Integr Comp Physiol 2010; 299: R953-9.
21. Yin J, Chen JD. Electroacupuncture improves rectal distension-induced delay in solid gastric emptying in dogs. Am J Physiol Regul Integr Comp Physiol 2011; 301: R465-72.
22. Sun Y, Song G, Yin J et al. Effects and mechanisms of electroacupuncture on glucagon-induced small intestinal hypomotility in dogs. Neurogastroenterol Motil 2010; 22: 1217-23, e1318.
23. Camilleri M, Bharucha AE, Ueno R et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G942-7.
24. Rickels K, Montgomery SA, Tourian KA et al. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol 2010; 30: 18-24.
25. Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol 2009; 24: 296-305.
26. Ferguson JM, Tourian KA, Rosas GR. High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectr 2012; 17: 121-30.
27. Pae CU. Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother 2011; 12: 2923-8.
28. Xu J, Dz Chen J. Effects of sibutramine on gastric emptying, intestinal motility and rectal tone in dogs. Dig Dis Sci 2008; 53: 155-62.
29. Xu J, Chen JD. Peripheral mechanisms of sibutramine involving proximal gastric motility in dogs. Obesity (Silver Spring) 2006; 14: 1363-70.
30. Teschemacher AG. Real-time measurements of noradrenaline release in periphery and central nervous system. Auton Neurosci 2005; 117: 1-8.
31. Tsukada F, Nagura Y, Abe S, Sato N, Ohkubo Y. Effect of restraint and footshock stress and norepinephrine treatment on gastric emptying in rats. Biol Pharm Bull 2003; 26: 368-70.
32. Vazquez Roque MI, Camilleri M, Clark MM et al. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol Hepatol 2007; 5: 829-37.
33. Scheibner J, Trendelenburg AU, Hein L, Starke K, Blandizzi C. Alpha 2-adrenoceptors in the enteric nervous system: a study in alpha 2A-adrenoceptor-deficient mice. Br J Pharmacol 2002; 135: 697-704.
34. Choudhury BK, Shi XZ, Sarna SK. Norepinephrine mediates the transcriptional effects of heterotypic chronic stress on colonic motor function. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1238-47.
35. Parker GB, Brotchie HL, Hyett M. Tolerance to desvenlafaxine in rapid metabolizing depressed patients. Int Clin Psychopharmacol 2010; 26: 84-7.
36. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009; 14: 183-95.
37. Chial HJ, Camilleri M, Burton D, Thomforde G, Olden KW, Stephens D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003; 284: G130-7.